That was AI analysis of response in a a P2a trial that was completed years ago.
The lead author,Hampel, is Eisai's diagnostic expert. His goal is not to show efficacy, it is to show the critera for measuring disease progression and improvement.
It appears that Eisai will probably be working with Anavex.
Market Data 
Markets 
AI
